More broadly, possibly through the control of cytokine signaling, PML contributes to the cross-talk between the tumor and the microenvironment (Guarnerio et al., 2018) and could modulate response to immune therapies, as proposed for inhibitors of sumoylation (Lightcap et al., 2021). The gene discussed is PML; the disease is neoplasm.